Introduction {#Sec1}
============

Patients presenting with acute pancreatitis (AP) are at risk of local and systemic complications, some of which persist beyond the hospital admission \[[@CR1]\]. This includes both endocrine and exocrine pancreatic insufficiency (EPI). Recent studies have shown that prediabetes and diabetes mellitus (DM) occur following the first attack of AP in up to 40% patients and increase over 5 years \[[@CR2]\]; they are associated with a marked reduction in the quality of life \[[@CR3], [@CR4]\]. Another study found that 10% of first-attack AP patients will then develop chronic pancreatitis \[[@CR5]\]. A recent meta-analysis \[[@CR6]\] investigated EPI after AP, but not during hospital admission, and found that a quarter of all AP patients develop EPI during follow-up. The risk of EPI is higher when patients have alcoholic etiology, severe and necrotizing pancreatitis.

The prevalence of EPI following AP and the use of pancreatic enzyme replacement therapy (PERT) are variably reported in the literature. The aim of this study was to undertake a systematic review and meta-analysis to determine the prevalence of EPI using formal exocrine function tests during AP hospitalization and follow-up to determine the contributing factors and time course and define strategies for PERT to treat EPI after AP.

Methods {#Sec2}
=======

Data Sources and Searches {#Sec3}
-------------------------

This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria \[[@CR7]\]. Electronic databases (Scopus, Embase and Medline) were searched (IB-R, CC-S and JL-N) for relevant studies from 1 January 1946 to 31 July 2018. References from searched studies were also examined. The keywords are listed in Supplementary Methods. Two authors (WH and DdlI-G) scrutinized all identified studies independently and agreed on those for inclusion. Citations from included studies and relevant reviews were also evaluated. When there was a discrepancy, the senior authors (JED-M and RS) arbitrated.

Study Selection {#Sec4}
---------------

Included studies fulfilled the following criteria: (1) prospective observational studies or randomized clinical trials (RCTs) of PERT that reported on EPI during the index admission (between the start of oral refeeding and before discharge) or follow-up (≥ 1 month after discharge) for AP in adults; (2) EPI diagnosed by direct and/or indirect laboratory exocrine function tests \[[@CR8], [@CR9]\]; (3) with multiple publications with overlapping patient groups the most recent study was included unless an earlier study had a larger sample size. Editorials, expert opinions, reviews, abstracts, case reports, letters, small sample size (\< 10 patients), pre-existing EPI, population-based studies and retrospective studies were excluded.

Data Extraction and Quality Assessment {#Sec5}
--------------------------------------

Two authors (WH and DdlI-G) independently collected data from included studies using a standardized pro forma designed by two senior authors (JED-M and RS). The data items are provided in Supplementary Methods. Three authors (XZ, NS and WC) independently scored the included studies, and two further authors (WH and DdlI-G) resolved any disagreement. The quality of observational studies was assessed using the Newcastle-Ottawa scale \[[@CR10]\] with a total score ≥ 5 (up to 4 for selection, 2 for comparability and 3 for outcome) indicative of high quality; the quality of RCTs was assessed using the Jadad system \[[@CR11]\] with a total score ≥ 3 (randomization 0 or 1; allocation concealment 0 or 1; double blinding 0, 1 or 2; recording of dropouts and/or withdrawals 0 or 1) indicative of high quality.

Outcomes of Interest {#Sec6}
--------------------

The primary outcome was the number (proportion) of patients diagnosed with EPI following development of AP during both hospitalization for the first attack of AP and follow-up. EPI was diagnosed by either direct pancreatic function tests, including the Lundh meal test, secretin-caerulein (or pancreozymin) test (SCT), amino acid consumption test (AACT), fecal chymotrypsin test or fecal elastase-1 (FE-1) test, or indirect tests including the triolein breath test, serum fluorescein-dilaurate test, serum pancreolauryl test, urinary pancreolauryl test, urinary *N*-benzoyl-[l]{.smallcaps}-tyrosyl-*P*-aminobenzoic acid (NBP-PABA) test, urinary [d]{.smallcaps}-xylose excretion test and fecal fat excretion (FFE) test. An FE-1 of 100--200 µg/g was defined as mild to moderate EPI and \< 100 µg/g as severe EPI.

Secondary outcomes included symptoms of EPI \[[@CR12]\], treatment with PERT \[[@CR12]\], recurrence of AP \[[@CR1], [@CR13]\], new-onset prediabetes and/or DM \[[@CR2], [@CR14]\], changes in pancreatic morphology, quality of life and employment status.

Definition of AP Severity, Complications and Pancreatic Intervention {#Sec7}
--------------------------------------------------------------------

AP was classified as severe when fulfilling one or more of the following criteria: (1) the "severe" category of the original Atlanta classification (OAC) \[[@CR15]\]; (2) the "moderately severe" and "severe" grades of the revised Atlanta classification (RAC) \[[@CR16]\]; (3) the presence of necrosis (\> 30%), pseudocyst or abscess; (4) a clinical severity score, imaging severity indices or biomarkers greater than their respective cutoff values. Other cases of AP were classified as mild. Studies were analyzed separately if they only included infected pancreatic necrosis (IPN), and IPN was defined as those with definitive diagnosis of pancreatic infection \[[@CR17]\] and/or unresolving sterile necrosis that was treated by pancreatic necrosectomy that became infected \[[@CR17], [@CR18]\]. Necrosectomy included open and minimally invasive procedures, while conservative management included no procedure, percutaneous drainage or an endoscopic procedure only \[[@CR19]\].

Data Synthesis and Statistical Analysis {#Sec8}
---------------------------------------

Pooled data were expressed as prevalence with 95% confidence interval (CI). Data for two group comparisons were expressed as relative risk (RR) or risk difference (RD) with 95% CI. Stats Direct V3.1 (StatsDirect Ltd, Cheshire, UK) was used to generate forest plots of pooled data using a random effects model to deliver the most conservative estimates. Heterogeneity was evaluated using *χ*^2^. *P* \< 0.1 was considered significant. Statistical heterogeneity was assessed using *I*^2^ values with cutoffs of 25%, 50% and 75% to indicate low, moderate and high heterogeneity, respectively \[[@CR20]\]. Meta-analyses generated the RR and RD for each comparison between two groups. For studies of EPI during the index admission and follow-up, the prevalence of EPI during the index admission was compared with EPI during follow-up between gallstone versus alcohol etiology and OAC mild versus severe AP. For all the follow-up studies, the prevalence of EPI was compared between females versus males; gallstones versus alcohol etiology; OAC mild versus severe AP; RAC mild versus moderate to severe AP; edematous versus necrotizing AP; necrosis \< 50% versus necrosis ≥ 50%; necrosis in the head versus body and/or tail; conservative management versus necrosectomy. Pooled prevalence of recurrent AP, pre-diabetes and/or DM and pancreatic morphologic changes were also generated.

Subgroup analyses examined high-quality studies, studies with sample sizes ≥ 40, Western population, etiology (gallstone or alcohol) and follow-up periods (up to 12 months, \> 12--36 months, \> 36--60 months and \> 60 months). Sensitivity analyses considered studies restricted to first AP episodes, pre-existing DM, studies with a proportion of patients undergoing pancreatic intervention for necrosis and/or infection during the index admission, direct EPI tests, indirect EPI tests, FFE test only and FE-1 test only.

Meta-regression analyses determined the impact of publication year, patient age, gender, AP etiology, disease severity, type of EPI test and study quality on the pooled prevalence estimate using Stata SE version 13 software (StataCorp LP, College Station TX, USA); *P* \< 0.05 was considered significant. Publication bias was assessed visually by funnel plots \[[@CR21]\] and using *P* values generated from the pooled prevalence of EPI during index admission and follow-up as well as by subgroups according to Begg-Mazumdar \[[@CR22]\] and Egger et al. \[[@CR23]\]; *P* \< 0.05 was considered significant.

Results {#Sec9}
=======

Characteristics of Included Studies {#Sec10}
-----------------------------------

A PRISMA flow diagram for study selection is shown in Fig. [1](#Fig1){ref-type="fig"}. A final total of 41 studies \[[@CR24]--[@CR64]\] from 16 countries were included. The study designs are summarized in Table [1](#Tab1){ref-type="table"}. Thirty-seven studies were published in English, two \[[@CR27], [@CR29]\] in Spanish, one \[[@CR41]\] in Italian and one \[[@CR59]\] in Russian. There were two RCTs \[[@CR30], [@CR55]\] for PERT versus placebo and one for the endoscopic versus surgical step-up approach \[[@CR64]\]. Ten studies \[[@CR36], [@CR44], [@CR46], [@CR47], [@CR49], [@CR51], [@CR53], [@CR54], [@CR57], [@CR64]\] had a consecutive cohort design, and the remainders were non-consecutive cohort studies. Three studies \[[@CR55], [@CR56], [@CR64]\] were multicenter. The shortest median follow-up was 1 month \[[@CR27]\] and the longest 180 months \[[@CR51]\]. Ten studies \[[@CR25], [@CR27], [@CR29]--[@CR31], [@CR40], [@CR44], [@CR48], [@CR49], [@CR55]\] assessed EPI during hospitalization and 39 studies \[[@CR24]--[@CR48], [@CR50]--[@CR54], [@CR56]--[@CR64]\] during follow-up.Fig. 1Preferred reporting items for the systematic reviews flow chart of study selection for this systematic reviewTable 1Design and quality assessment of included studiesStudyYearCountryFollow-up designSingle or multicenterIndex hospitalization period of source cohortStudy AP population^a^Type of comparisonFollow-up time (months)^b^Quality scoreBraganza et al.1973UKProspective cohortSingleNRNRNone\> 3NOS, 6Seligson et al.1982SwedenProspective cohortSingle1969--1978Severe^c^None59 (18--108)NOS, 5Mitchell et al.1983UKProspective cohortSingleNRAll severityIndex admission versus follow-up; mild versus severe; biliary versus alcoholIndex admission, 2--12NOS, 6Angelini et al.1984ItalyProspective cohortSingleNRSevere^c^Biliary versus alcohol13--36NOS, 5Arenas et al.1986SpainProspective cohortSingeNRAll severityIndex admission versus follow-up; biliary versus alcoholIndex admission, 1NOS, 4Büchler et al.1987GermanyProspective cohortSingle1981 to 1985All severityEdematous versus necrotizing; biliary versus alcohol2--12, 13--40NOS, 6Garnacho Montero et al.1989SpainProspective cohortSingleNRAll severity; biliary and alcoholIndex admission versus follow-up; biliary versus alcoholIndex admission, 3--12NOS, 6Airely et al.1991UKProspective RCTSingleNRMild^c^Index admission versus follow-up; placebo versus PERTIndex admission, 1.5Jadad, 3Glasbrenner et al.1992GermanyProspective cohortSingleNRMild^c^Index admission versus follow-up; biliary versus alcoholIndex admission, 1.5NOS, 5Bozkurt et al.1995GermanyProspective cohortSingleNRIPNNone3--12, 18NOS, 5Seidensticker et al.1995GermanyProspective cohortSingle1976 to 1992All severityBiliary versus alcohol\< 12, 12--60, \> 60NOS, 5Malecka-Panas et al. (a)1996PolandProspective cohortSingleNRSevere^c^; alcoholNone48--84NOS, 4Malecka-Panas et al. (b)1996PolandProspective cohortSingleNRAll severity; biliaryNone6--12; 36--60NOS, 4John et al.1997South AfricaProspective consecutive cohortSingleNRAll severityNone9 (2--16)NOS, 4Tsiotos et al.1998USAProspective cohortSingle1983 to 1995IPNNone48 (3--132)NOS, 5Appelros et al.2001SwedenProspective cohortSingle1985 and 1994Severe^c^None84 (24--144)NOS, 4Ibars et al.2002SpainProspective cohortSingleJuly 1994 to December 1995All severity; biliaryMild versus severe6--12NOS, 6Boreham et al.2003UKProspective cohortSingleDecember 2000 to November 2001All severityIndex admission versus follow-up; mild versus severeIndex admission, 3NOS, 7Napolitano et al.2003ItalyProspective cohortSingleNRMild^c^; biliaryNone48NOS, 7Sabater et al.2004SpainProspective cohortSingle1994 to 1998Severe (included a proportion of IPN)^c^; biliaryConservative versus necrosectomy12NOS, 8Migliori et al.2004ItalyProspective cohortSingleNRAll severity; biliary and alcoholEdematous versus necrotizing; biliary versus alcohol18NOS, 6Bavare et al.2004IndiaProspective consecutive cohortSingleJanuary 2001 to June 2003IPNIndex admission versus follow-upIndex admission, 6--12, 13--18NOS, 5Symersky et al.2006NetherlandsProspective cohortSingle1990 to 1996All severity; nonalcoholicMild versus severe55 (12--90)NOS, 4Reszetow et al.2007PolandProspective consecutive cohortSingleJanuary 1993 to December 1999IPN; biliary and alcoholBiliary versus alcohol; female versus male61 (24--96)NOS, 5Reddy et al.2007IndiaProspective consecutive cohortSingle1996 to 1998IPNBiliary versus alcohol; female versus male22 (15--36)NOS, 5Pelli et al.2009FinlandProspective cohortSingleJanuary 2001 to February 2004All severity, alcoholicIndex admission versus follow-up; mild versus severeIndex admission, 24NOS, 5Pezzilli et al.2009ItalyProspective consecutive cohortSingleJanuary 2006 to December 2006All severityMild versus severe; biliary versus alcohol; female versus maleIndex admissionNOS, 3Gupta et al.2009IndiaProspective cohortSingleJuly 2005 to December 2006 (and prior to 2005)Severe (included a proportion of IPN)^c^Conservative versus necrosectomy31 (7--118)NOS, 4Uomo et al.2010ItalyProspective consecutive cohortSingleJanuary 1994 to December 2006Severe^c^None180 (156--203)NOS, 6Andersson et al.2010SwedenProspective cohortSingle2001--2005All severityMild versus severe42 (36--53)NOS, 8Xu et al.2012ChinaProspective consecutive cohortSingle2003 to 2008All severityMild versus severe29NOS, 7Garip et al.2013TurkeyProspective consecutive cohortSingleMarch 2003 to October 2007All severityMild versus severe; edematous versus necrotizing32 (6--48)NOS, 6Kahl et al.2014GermanyProspective RCTMulticenterNRAll severityPlacebo versus PERTIndex admissionJadad, 4Vujasinovic et al.2014SloveniaProspective cohortMulticenterNRAll severityMild versus severe (mild versus moderate versus severe^d^); biliary versus alcohol; female versus male32NOS, 5Winter Gasparoto et al.2015BrazilProspective consecutive cohortSingleJanuary 2002 to April 2012Severe^c^None35 (12--90)NOS, 4Chandrasekaran et al.2015IndiaProspective cohortSingleJuly 2009 to December 2010Severe (included a proportion of IPN)^c^Conservative versus necrosectomy26 ± 18NOS, 8Ermolov et al.2016RussiaProspective cohortSingle2003 to 2012Severe (included a proportion of IPN)^c^Conservative versus necrosectomy102 ± 36NOS, 6Nikkola et al.2017FinlandProspective cohortSingleJanuary 2001 to February 2005All severity; alcoholicMild versus severe^d^126 (37--155)NOS, 5Koziel et al.2017PolandProspective cohortSingle2011 and 2012Mild and severeMild versus severe (mild versus moderate to severe^d^); biliary versus alcohol14 ± 4NOS, 8Tu et al.2017ChinaProspective cohortSingleJanuary 2016 to April 2016All severity (included a proportion of IPN)Mild versus moderate versus severe^d^43 ± 4NOS, 5van Brunschot et al.2018NetherlandProspective RCTMulticenterSeptember 2011 to January 2015Infected pancreatic necrosisEndoscopic versus surgical step up approach6Jadad, 5*AP* acute pancreatitis, *NOS* Newcastle-Ottawa Scale, *NR* not reported, *RCT* randomized controlled trial, *PERT* pancreatic enzyme replacement therapy, *IPN* infected pancreatic necrosis and/or unresolving sterile necrosis that needed necrosectomy and became infected^a^Included all etiologies if not otherwise stated^b^Index admission refers to between the start of oral refeeding and before discharge^c^Severe was defined by original Atlanta classification or the authors own clinical criteria^d^Severe was defined by the revised Atlanta classification

Of the 38 studies scored by the Newcastle-Ottawa scale with Selection, Comparability and Outcome compositions (Supplementary Table 1A), 32 (84%) were of high quality \[[@CR24]--[@CR29], [@CR31]--[@CR54], [@CR56]--[@CR62], [@CR64]\]. The three RCTs \[[@CR30], [@CR55], [@CR64]\] were all of high quality (Supplementary Table 1B). Regarding the *Selection* section, 22 (58%) studies had no *"selection of the non*-*exposed cohort*," while 35 (92%) did not report *"demonstration that outcome of interest was not present at start of study."* In the *Comparability* section, 33 (87%) did not show *"comparability of cohorts on the basis of the design or analysis."* In the *Outcome* section, ten had no *"adequacy of follow*-*up of cohorts."*

Characteristics of Included Patients {#Sec11}
------------------------------------

The overall baseline characteristics of patients are shown in Table [2](#Tab2){ref-type="table"}. For ten inpatient studies, the pooled median age was 51 years (males, 59%); etiology was 70% gallstones, 17% alcohol and 13% other causes; six studies were restricted to first AP episodes \[[@CR30], [@CR31], [@CR40], [@CR44], [@CR48], [@CR49]\], while four \[[@CR25], [@CR27], [@CR29], [@CR55]\] did not report. For the 39 follow-up studies, the pooled median age was 51 years (males, 63%); etiology was 55% gallstone, 28% alcohol and 17% other causes; 16 studies were restricted to first AP episodes \[[@CR30]--[@CR34], [@CR39], [@CR40], [@CR43]--[@CR46], [@CR48], [@CR50], [@CR53], [@CR57], [@CR60]\], while 5 \[[@CR28], [@CR35], [@CR38], [@CR56], [@CR62]\] were not so restricted, and the remaining 18 \[[@CR24]--[@CR27], [@CR29], [@CR36], [@CR37], [@CR41], [@CR42], [@CR47], [@CR51], [@CR52], [@CR54], [@CR58], [@CR59], [@CR61], [@CR63], [@CR64]\] did not report.Table 2Baseline characteristics of patients in the included studiesStudyPatients enrolled (analyzed for EPI)Age, year^a^Male, *n* (%)BiliaryAlcoholicOthersFirst AP episodeSeverity criteriaSeverity statusBraganza et al.12 (12)NRNRNRNRNRNRNRNRSeligson et al.10 (10)54 ± 128 (80)271NRNecrotizing AP10 severeMitchell et al.30 (30)22--8915 (50)13611NRClinical complication25 mild, 5 severeAngelini et al.27 (20)^b^NR24 (89)^b^14^b^10^b^3^b^NRNecrotizing AP27 severeArenas et al.26 (26)24--829 (35)1647NRNRNRBüchler et al.79 (79)4648 (61)283714Partially^c^Necrotizing AP27 edematous, 32 minor necrotizing, 20 major necrotizingGarnacho Montero et al.19 (19)23--759 (47)1180NRNRNRAirey et al.59 (41)62 (30--82)19 (46)3065AllLocal or systemic complication41 mild, 0 severeGlasbrenner et al.29 (29)37 (22--68)17 (59)15140AllPancreatic necrosis and CRP \> 120 mg/lMean ranson score 1.6Bozkurt et al.89 (53)^b^21--83^b^59 (66)^b^21^b^56^b^12^b^AllIPN53 IPNSeidensticker et al.38 (38)41 ± 1425 (66)81614AllRanson score \> 321 ranson score ≤ 3, 4 ranson score \> 3Malecka-Panas et al. (a)47 (47)44 ± 1033 (70)4700AllImrie criteria 3--447 severeMalecka-Panas et al. (b)30 (30)53 ± 178 (27)3000Partially (70%)Imrie criteria ≥ 3NRJohn et al.50 (50)3938 (76)5423NROACNRTsiotos et al.72 (44)58 (20--93)33 (75)17522NRIPN44 IPNAppelros et al.79 (26)60 (27--92)^b^52 (66)^b^19^b^30^b^30^b^Partially (87%)OAC79 severe^b^Ibars et al.63 (61)62 ± 14^b^17 (27)^b^63^b^0^b^0^b^AllOAC and area of necrosis45 mild, 18 severe; 6 necrosis 30--50%, 3 necrosis ≥ 50%^b^Boreham et al.23 (23)55 (21--77)13 (57)1553AllOAC16 mild, 7 severeNapolitano et al.35 (35)NRNR3500NRNRNRSabater et al.39 (27)No surgery: 61 ± 14; necrosectomy: 64 ± 1112 (44.4)2700NROAC; IPN27 severe (11 necrosis ≥ 50%); 12 IPN, 15 sterile necrosisMigliori et al.75 (75)46 (17--80)57 (76)39360AllNecrotizing AP42 edematous, 33 necrotizingBavare et al.18 (18)36 (25--47)18 (100)4104AllIPN18 IPNSymersky et al.34 (34)53 ± 316 (47)2608AllOAC22 mild, 12 severeReszetow et al.28 (28)48 ± 1020 (71)10180AllIPN28 IPN (26 APACHE II \> 8)Reddy et al.10 (10)35 (22--47)8 (80)460NRIPNIPN (5 necrosis \< 50%, 4 necrosis ≥ 50%, 1 unspecified)Pelli et al.54 (54)49 (25--71)47 (87)5400AllOAC41 mild, 13 severePezzilli et al.75 (75)62 (20--94)37 (49)61113AllOAC60 mild, 15 severeGupta et al.30 (30)38 ± 224 (80)12135AllOAC; IPN22 IPN, 8 sterile necrosisUomo et al.65 (40)48±1817 (42.5)28012NRNR25 necrosis \< 50%, 15 necrosis ≥ 50%Andersson et al.40 (40)61 (48--68)16 (40)201010NROAC26 mild (3 APACHE II ≥ 8), 14 severe (9 APACHE II ≥ 8)Xu et al.65 (65)59 (27--82)33 (51)5078AllOACMild 27, severe 38Garip et al.109 (109)57 ± 1658 (53)72928NRAPACHE II ≥ 839 severe (APACHE II ≥ 8), 70 mild (APACHE II \< 8); necrosis 30Kahl et al.56 (55)51 (23--81)34 (62)NRNRNRNRAPACHE II ≥ 4; CRP \> 120 mg/LPlacebo: APACHE II 5.1 ± 3.2, CRP 172 ± 108 mg/l; PERT: APACHE II 5.3 ± 2.9, CRP 176 ± 79 mg/lVujasinovic et al.100 (100)58 ± 1265 (65)364222Partially (75%)RAC67 mild, 15 moderate, 18 severeWinter Gasparoto et al.16 (16)48 ± 139 (56)1040YesAPACHE II ≥ 8 or 12 CRP ≥ 150 mg/l4 APACHE II ≥ 8, 12 CRP ≥ 150 mg/l; 9 necrosis \< 30%, 4 30--50%, 3 ≥ 50%Chandrasekaran et al.35 (35)37 ± 1030 (86)11195NROAC; IPN35 severe (1 necrosis \< 30%, 7 30--50%, 27 ≥ 50%; 15 APACHE II \< 8, 20 APACHE II \> 8); 21 IPN, 14 sterile necrosisErmolov et al.210 (80)^b^55 ± 13^b^144 (69)^b^NRNRNRNROAC; IPNSevere 210^b^; 34 IPNNikkola et al.77 (45)48 (25--71)69 (90)4500AllRAC53 mild, 20 moderate, 4 severeKoziel et al.150 (150)53 ± 1594 (63)644640NRRAC51 mild, 99 severeTu et al.113 (113)47 ± 175 (66)65345Partially (83%)RAC; IPN10 mild, 12 moderate, 91 severe (73 IPN)van Brunschot et al.98 (83)62 ± 1363 (64)56 (57)14 (14)28 (29)NRRAC55 moderate, 43 severe*EPI* exocrine pancreatic insufficiency, *AP* acute pancreatitis, *NR* not reported, *CRP* C-reactive protein, *IPN* infected pancreatic necrosis, *OAC* original Atlanta classification, *APACHE* Acute Physiology and Chronic Health Evaluation, *PERT* pancreatic enzyme replacement therapy, *RAC* revised Atlanta classification^a^Year is expressed as mean (standardized deviation), mean (range), median (range) or range^b^Data are derived from original enrolled patients rather than actual analyzed patients^c^Included two cases of chronic pancreatitis

Pancreatic Function During Admission and Follow-Up {#Sec12}
--------------------------------------------------

Detailed pancreatic function data and clinical outcomes at follow-up are shown in Table [3](#Tab3){ref-type="table"}. For the 10 inpatient studies, 1 \[[@CR48]\] reported pre-existing DM in 8 of 54 patients (15%), 2 \[[@CR40], [@CR49]\] reported none, and the remaining studies \[[@CR25], [@CR27], [@CR29]--[@CR31], [@CR44], [@CR55]\] did not report; 2 \[[@CR44], [@CR49]\] had a proportion of patients who had undergone pancreatic interventions, 4 \[[@CR25], [@CR30], [@CR31], [@CR40]\] had none, and 4 \[[@CR27], [@CR29], [@CR48], [@CR55]\] did not report.Table 3Pancreatic function at baseline and follow-upStudyPatients enrolled (analyzed for EPI)Pre-existing DM (%)Pancreatic intervention (%)^a^EPI diagnostic criteriaEPI (%)^b^Use of PERTRAP (%)New prediabetes and/or DM (%)Pancreatic morphology changes (%)Health statusBraganza et al.12 (12)NR0 (0)SCT \< lower reference range^c^1 (0.8)NRNRNRNRNRSeligson et al.10 (10)1 (10)NRLundh meal test \< lower reference range^d^7 (70)2 (20)NR5 (50)6 (60)NRMitchell et al.30 (30)NR0 (0)NBT-PABA test with urinary PABA recovery \< 57%7/15 (47); Index admission: 30 (100)NRNRNRNRNRAngelini et al.27 (20)NR27 (100)^e^SCT \< lower reference range^c^8/20 (40)NRNR12 (44)^e^13 (48)^e^NRArenas et al.26 (26)NRNRNBT-PABA test with urinary PABA recovery \< 45%2/11 (18) Index admission: 12 (46)NRNRNRNRNRBüchler et al.79 (79)NR52 (65.8)SCT \< lower reference range^c^; urine or serum fluorescein-dilaurate test \< lower reference range (NR)42 (53)NRNR19 (24)34 (43)NRGarnacho Montero et al.19 (19)NRNRNBT-PABA test with urinary PABA recovery \< 45%8 (42); Index admission: 19 (100)NRNRNRNRNRAirey et al.59 (41)NR0 (0)NBT-PABA test with urinary PABA recovery \< 55%29 (71); Index admission: 26 (63)20 (49)^f^NRNRNRNRGlasbrenner et al.29 (29)NR0 (0)Fluorescein dilaurate test with peak serum fluorescein \< 4.5 µg/ml; fecal chymotrypsin \< 3 U/gIndex admission: 23 (79)0 (0)NRNRNRNRBozkurt et al.89 (53)NR42 (47)^d^Lundh meal test \< lower reference range^d^45 (85)NRNRNRNRNRSeidensticker et al.38 (38)NR1 (3)SCT \< lower reference range^c^5 (13)NR0 (0)NR7 (18)NRMalecka-Panas et al. (a)47 (47)NR0 (0)SCT \< lower reference range^c^30 (64)6 (13)NR14 (30)30 (64)NRMalecka-Panas et al. (b)30 (30)NRNRSCT \< lower reference range^c^19 (63)NRNRNR4 (13)NRJohn et al.50 (36)NRNRFecal chymotrypsin level \< 3 U/g11 (31)NRNRNR9 (18)NRTsiotos et al.72 (44)NR44 (100)FFE \> 7 g/d with or without fecal weight \> 20%11 (25)11 (25)2 (5)16 (36)NRECOG scoreAppelros et al.79 (26)1 (1)31 (39)Pathologic triolein breath test (1 point) with weight loss \> 10% (1 point), low level of serum amylase (1 point), low fat diet to avoid diarrhea (1 point); ≥ 218 (69)NR12 (34)19 (73)NRWorking capacityIbars et al.63 (61)NR0 (0)FFE \> 7 g/d; SCT \< lower reference range^c^; urinary pancreolauryl test \< 25%; fecal chymotrypsin \< 3 U/g2 (3)NRNR13 (21)NRNRBoreham et al.23 (23)0 (0)0 (0)FE-1 \< 200 µg/g^g^6 (26); Index admission: 8 (35)NRNR4 (17)NRNRNapolitano et al.35 (35)NR0 (0)FE-1 \< 200 µg/g4 (11)NRNR2 (6)NRNRSabater et al.39 (27)NR12 (44)FFE \> 7 g/d for 3 days; fecal chymotrypsin \< 6 U/g; SCT \< lower reference range^c^9 (33)NRNR13 (48)NRNRMigliori et al.75 (75)NR0 (0)SCT with bicarbonate \< 15 mmol, lipase \< 150 U × 10^3^; chymotrypsin \< 160 U × 10^2^; AACT \< 14%41 (55)NRNRNRNRNRBavare et al.18 (18)NR18 (100)FFE \> 7 g/d with or without steatorrhea and use of PERT9 (50); index admission: 13 (72)2 (11)3 (17)13 (72)16 (89)Back to workSymersky et al.34 (34)NR6 (18)FFE \> 7 g/d for 2 days; NBT-PABA test with urinary PABA \< 50%22 (65)10 (29)0 (0)12 (35)NRGIQLIReszetow et al.28 (28)0 (0)28 (100)FE-1 \< 200 µg/g^g^4 (14)NRNR22 (79)12 (42)Core FACIT scaleReddy et al.10 (10)0 (0)10 (100)FFE \> 7 g/d8 (80)NRNR5 (50)7 (70)Back to workPelli et al.54 (54)8 (15)NRFE-1 \< 200 µg/g with or without plasma fat-soluble vitamin A \< 1 µmol/l or vitamin E \< 12 µmol/l5 (9); index admission 21 (39)NR10 (19)17 (37)18 (51)NRPezzilli et al.75 (75)0 (0)5 (7)FE-1 \< 200 µg/g^g^Index admission: 9 (12)0 (0)NRNRNRNRGupta et al.30 (30)0 (0)25 (83)FFE \> 7 g/d; urinary [d]{.smallcaps}-xylose excretion \< 20%12 (40)4 (13)12 (40)12 (40)13 (43)NRUomo et al.65 (40)2 (5)19 (48)Serum pancreoauryl test \< 4.5 µg/ml; FE-1 \< 200 µg/g9 (23)0 (0)0 (0)6 (16)2 (5)NRAndersson et al.40 (40)1 (2.5)4 (10)FE-1 \< 200 µg/g1 (3)3 (8)NR22 (55)NRSF-36Xu et al.65 (65)0 (0)5 (8)FE-1 \< 200 µg/g^g^38 (59)33 (51)NRNR20 (31)NRGarip et al.109 (109)13 (12)5 (5)FE-1 \< 200 µg/g^g^15 (14)NRNR33 (30)NRNRKahl et al.56 (56)NRNRFE-1 \< 200 µg/gIndex admission: 20 (36)26 (46)^f^NRNRNRFACT-PaVujasinovic et al.100 (100)NRNRFE-1 \< 200 µg/g^g^ with measuring serum iron, magnesium, folic acid and vitamins A, D, E and B1221 (21)NR25 (25)14 (14)NRNRWinter Gasparoto et al.16 (16)0 (0)5 (31)FFE with positive Sudan stain1 (6)1 (6)NR12 (75)2 (13)SF-36Chandrasekaran et al.35 (35)0 (0)21 (60)FFE \> 7 g/d14 (40)21 (60)3 (8.6)17 (48.6)NRNRErmolov et al.210 (80)NR136 (65)^e^FE-1 \< 200 µg/g^g^28 (35)NR58 (28)62 (30)12 (15)GIQLINikkola et al.77 (45)5 (7)^e^0 (0)FE-1 \< 200 µg/g11 (24)NR27 (35)^e^20 (26)^e^9 (12)^e^NRKoziel et al.150 (150)17 (11)18 (12)FE-1 \< 200 µg/g^g^21 (14)NR44 (29)18 (14)58 (39)SF-36Tu et al.113 (113)0 (0)73 (65)FE-1 \< 200 µg/g^g^40 (35)NRNR67 (59)NRNRvan Brunschot et al.98 (83)18 (18)98 (100)FE-1 \< 200 µg/g^g^41 (49)29 (35)NR19 (23)NRNR*EPI* exocrine pancreatic insufficiency, *DM* diabetic mellitus, *RAP* recurrent acute pancreatitis, *NR* not reported, *NBT*-*PABA N*-benzoyl-[l]{.smallcaps}-tyrosyl-*P*-aminobenzoic acid, *SCT* secretin-cerulein (or pancreozymin) test, *FFE* fecal fat excretion, *FE*-*1* fecal elastase-1, *AACT* amino acid consumption test, *PERT* pancreatic enzyme replacement therapy, *GIQLI* Gastrointestinal Quality of Life Index, *FACIT* Functional Assessment of Chronic Illness Therapy, *SF*-*36* Short Form 36 Health Survey Questionnaire, *FACT* Functional Assessment of Cancer Therapy^a^Included necrosectomy, drainage and local lavage procedures^b^Data refer to follow-up studies if not otherwise stated and with maximal numbers of EPI during observational period^c^Bicarbonate \< 70 mEq/l, lipase \< 97 kUI/h, chymotrypsin \> 11 kUI/h^d^Lundh test meal amylase \< 11,000 U/h, lipase \< 110,000 U/h and trypsin \< 7000 U/h^e^Data are derived from original enrolled patients rather than actual analyzed patients^f^Contained all the patients in the PERT arm in a randomized controlled trial comparing placebo versus PERT^g^These studies defined severity of EPI with FE-1 levels: 100--200 µg/g mild to moderate and \< 100 µg/g severe

In the 39 follow-up studies, body mass index, alcohol history, cigarette smoking and symptoms of EPI were rarely recorded (data not shown). Nine studies \[[@CR24], [@CR38], [@CR48], [@CR51], [@CR52], [@CR54], [@CR60], [@CR61], [@CR64]\] had a minor proportion of pre-existing DM (1.3--18%), 8 \[[@CR40], [@CR46], [@CR47], [@CR50], [@CR53], [@CR57], [@CR58], [@CR62]\] had none, and the remaining 22 \[[@CR25]--[@CR37], [@CR39], [@CR41]--[@CR45], [@CR56], [@CR59], [@CR63]\] did not report; 22 \[[@CR26], [@CR28], [@CR32], [@CR33], [@CR37], [@CR38], [@CR42], [@CR44]--[@CR47], [@CR50]--[@CR54], [@CR57]--[@CR59], [@CR61], [@CR62]\] had a proportion of patients who had undergone pancreatic interventions; 10 \[[@CR25], [@CR30], [@CR31], [@CR34], [@CR39]--[@CR41], [@CR43], [@CR60], [@CR63]\] reported no pancreatic interventions, and the remaining 7 \[[@CR24], [@CR27], [@CR29], [@CR35], [@CR36], [@CR48], [@CR56]\] did not report.

Results of the Meta-Analysis {#Sec13}
----------------------------

There were insufficient data for quantitative meta-analysis of the effects of PERT versus placebo in the two RCTs \[[@CR30], [@CR55]\]. The results of meta-analysis are shown in Table [4](#Tab4){ref-type="table"}.Table 4Results of meta-analysesVariableNo. of studiesNo. of patientsNo. of EPIEffect estimateHeterogeneityPool prevalence, % (95% CI)*I*^2^ (%)*P* valueOverall during index admission1037018362 (39--82)95\< 0.0001 Index admission versus follow-up^a^  Index admission824015471 (50--89)92\< 0.0001  Follow-up82106933 (17--53)88\< 0.0001 Mild versus severe (OAC)  Mild31013446 (0--99)98\< 0.0001  Severe3271366 (11--99)90\< 0.0001 Biliary versus alcohol  Biliary etiology51165172 (26--99)96\< 0.0001  Alcohol etiology6875087 (71--97)260.248Overall at follow-up39179561835 (27--43)91\< 0.0001 Mild versus severe (OAC)  Mild1346710021 (11--33)89\< 0.0001  Severe2384734542 (33--52)86\< 0.0001 Mild versus moderate to severe (RAC)  Mild41602416 (10--23)230.275  Moderate227727 (13--45)00.453  Severe32085830 (15--47)820.004 Biliary versus alcohol  Biliary etiology153357222 (12--33)81\< 0.0001  Alcohol etiology1438815544 (27--60)91\< 0.0001  Other etiologies3721319 (11--29)00.726 Female versus male  Female345623 (1--64)790.01  Male51194548 (26--71)820.0003 Edematous versus necrotizing versus IPN  Edematous82615424 (14--36)77\< 0.0001  Necrotizing1553824447 (36--58)84\< 0.0001  IPN1139818848 (35--62)86\< 0.0001 Necrosis \< 50% versus necrosis ≥ 50%  \< 50%61214941 (17--68)86\< 0.0001  ≥ 50%6814558 (34--79)760.001 Head versus body and/or tail  Head320841 (22--62)00.661  Body/tail3792734 (11--61)700.036 Conservative versus necrosectomy  Conservative4741623 (12--35)240.267  Necrosectomy91837348 (32--63)77\< 0.0001 Recurrent AP1393718824 (17--31)82\< 0.0001 Prediabetic and/or DM versus EPI^b^  Prediabetes and/or DM27145449438 (31--45)87\< 0.0001  EPI27135740932 (24--40)90\< 0.0001 Pancreatic morphologic changes1881027236 (27--45)87\< 0.0001*EPI* exocrine pancreatic insufficiency, *CI* confidence interval, *OAC* original Atlanta classification, *RAC* revised Atlanta classification, *IPN* infected pancreatic necrosis, *AP* acute pancreatitis, *DM* diabetic mellitus^a^Included studies that simultaneously reported prevalence of EPI during index admission and at follow-up^b^Included studies that simultaneously reported prevalence of EPI and prediabetic and/or DM

### Prevalence of EPI During Admission and Follow-Up {#Sec14}

In the 10 index admission studies, 389 patients were enrolled and 370 analyzed (Supplementary Figure 1A). The pooled prevalence of EPI was 62% (95% CI 39--82%), with high statistical heterogeneity among studies (*I*^2^ = 95%). Of the eight studies \[[@CR25], [@CR27], [@CR29]--[@CR31], [@CR40], [@CR44], [@CR48]\] that also provided data on EPI during follow-up, the pooled prevalence of EPI was 71% (50--89%) during the index admission and 33% (17--53%) during follow-up, respectively (Supplementary Figure 1B and 1C), showing that the prevalence of EPI halved (RD: − 0.34, − 0.53 to − 0.14) during follow-up (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Relative risk comparison for prevalence of exocrine pancreatic insufficiency during index admission of acute pancreatitis: **a** index admission versus follow-up, **b** biliary versus alcohol (original Atlanta classification, OAC) and **c** mild versus severe (OAC)

Five studies \[[@CR25], [@CR27], [@CR29], [@CR31], [@CR49]\] of EPI during the index admission compared alcohol versus gallstone etiology (RR: 1.79, 0.59--5.43, *P* = 0.35; Fig. [2](#Fig2){ref-type="fig"}b), and three \[[@CR25], [@CR40], [@CR49]\] compared OAC severe versus mild AP (RR: 2.9, 0.5--16.7, *P* = 0.24; Fig. [2](#Fig2){ref-type="fig"}c), both showing no significant difference. No data were quantitively synthesized for gender and necrosis.

### Prevalence of EPI During Follow-Up Alone {#Sec15}

In the 39 follow-up studies, 2168 patients were enrolled and 1795 analyzed (Table [4](#Tab4){ref-type="table"} and Supplementary Figure 2). The pooled prevalence of EPI was 35% (27--43%), with high statistical heterogeneity among studies (*I*^2^ = 92%). The pooled prevalence of EPI was 21% for OAC mild AP (13 studies) (Supplementary Figure 3A), 42% for OAC severe AP (23 studies) (Supplementary Figure 3B), 16% for RAC mild AP (4 studies) (Supplementary Figure 4A), 27% for RAC moderately severe AP (2 studies) (Supplementary Figure 4B) and 30% for RAC severe AP (3 studies) (Supplementary Figure 4C). The pooled prevalence of EPI was 24% for edematous AP (8 studies) (Supplementary Figure 5A), 47% for necrotizing AP (15 studies) (Supplementary Figure 5B) and 48% for IPN (11 studies) (Supplementary Figure 5C).

There was no significant difference in the prevalence of EPI during follow-up for gender (RR: 1.5, 0.4--6.3, *P *\> 0.5; 3 studies) \[[@CR46], [@CR47], [@CR56]\] (Table [4](#Tab4){ref-type="table"}). There was a significantly higher prevalence of EPI for patients with alcohol etiology compared with gallstones (RR: 1.6, 1.1--2.3, *P* = 0.01; 11 studies) \[[@CR26], [@CR28], [@CR29], [@CR31], [@CR33]--[@CR35], [@CR43], [@CR46], [@CR47], [@CR56], [@CR61]\] (Fig. [3](#Fig3){ref-type="fig"}a). There was a higher prevalence of EPI in patients with OAC severe AP versus mild AP (RR: 1.5, 1.2--2, *P* = 0.003, 10 studies) \[[@CR40], [@CR45], [@CR48], [@CR52]--[@CR54], [@CR56], [@CR60]--[@CR62]\] (Fig. [3](#Fig3){ref-type="fig"}b); in RAC moderately severe/severe versus mild AP (RR: 2, 1.1--3.4, *P* = 0.018, 3 studies) \[[@CR56], [@CR61], [@CR62]\] (Fig. [3](#Fig3){ref-type="fig"}c); in necrotizing versus edematous AP (RR: 1.8, 1--3.2, *P* = 0.06; 6 studies) \[[@CR28], [@CR40], [@CR43], [@CR50], [@CR54], [@CR62]\] (Fig. [4](#Fig4){ref-type="fig"}a). There was no significant difference in the prevalence of EPI for ≥ 50% necrosis versus \< 50% necrosis (RR: 1.2, 1--1.6, *P* = 0.172, 6 studies) \[[@CR28], [@CR40], [@CR46], [@CR47], [@CR50], [@CR62]\] (Fig. [4](#Fig4){ref-type="fig"}b), for pancreatic head versus body and/or tail necrosis (RR: 1.1, 0.6--2, *P *\> 0.5; 3 studies) \[[@CR46], [@CR47], [@CR62]\] (Table [4](#Tab4){ref-type="table"}) or for patients having necrosectomy versus conservative management (RR: 1.62, 0.8--3.44, *P* = 0.205; 5 studies) \[[@CR42], [@CR50], [@CR58], [@CR59], [@CR64]\] (Fig. [4](#Fig4){ref-type="fig"}c).Fig. 3Relative risk comparison for prevalence of exocrine pancreatic insufficiency for all follow-up studies of acute pancreatitis: **a** biliary versus alcohol (original Atlanta classification, OAC), **b** mild versus severe (OAC) and **c** mild versus moderate to severe (revised Atlanta classification, RAC)Fig. 4Relative risk comparison for prevalence of exocrine pancreatic insufficiency at follow-up focused on acute necrotizing pancreatitis: **a** edematous versus necrotizing; **b** necrosis \< 50% versus ≥ 50%; **c** conservative management (mgt) versus necrosectomy

The pooled prevalence for recurrent AP, pre-diabetes and/or DM and pancreatic morphologic changes was 24% (17--31%), 38% (31--45%) and 36% (27--45%), respectively (Table [4](#Tab4){ref-type="table"}). In the studies \[[@CR24], [@CR26], [@CR28], [@CR34], [@CR37]--[@CR42], [@CR44]--[@CR48], [@CR50]--[@CR52], [@CR54], [@CR56]--[@CR62]\] that reported on the occurrence of EPI and new-onset pre-diabetes and/or DM, the pooled prevalence of EPI was 32% (24--40%), without any statistically significant difference between the two (RR of EPI in patients developing new-onset pre-diabetes and/or DM: 0.8, 0.7--1.1, *P* = 0.33) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Relative risk comparison for prevalence of exocrine pancreatic insufficiency (EPI) versus pre-diabetes and/or diabetes mellitus (DM) for all follow-up studies of acute pancreatitis that reported these two parameters simultaneously

In eight studies \[[@CR40], [@CR46], [@CR53], [@CR54], [@CR56], [@CR59], [@CR61], [@CR62]\] that reported the severity of EPI and used the FE-1 test, the pooled prevalence of mild to moderately severe EPI was 16% (CI 10--24%) (Supplementary Figure 6A) and of severe EPI was 11% (CI 6--17% (Supplementary Figure 6B).

The prevalence of EPI for long-term follow-up is shown in Fig. [6](#Fig6){ref-type="fig"} and Supplementary Table 2. These data demonstrate that there was a steady decrease in the prevalence of EPI after AP from the index admission over the subsequent 5 years of follow-up (OAC severe AP 59--38%, OAC mild AP 56--18%), but beyond 5 years there was a modest rise in prevalence.Fig. 6Time course of the pooled prevalence of exocrine pancreatic insufficiency during and for \> 5 years after an attack of acute pancreatitis obtained from all included studies

Subgroup Analyses {#Sec16}
-----------------

Subgroup analyses found that study quality, sample size and Western population did not affect the primary meta-analysis results (Supplementary Table 2). Gallstone etiology had a decreased prevalence of EPI compared with the primary analysis, whereas alcohol etiology had an increased prevalence of EPI. None of these factors significantly affected the statistical heterogeneity.

Sensitivity Analyses {#Sec17}
--------------------

Sensitivity analyses found that in the studies that used the FE-1 test there was a lower pooled prevalence of EPI (Supplementary Table 3). In contrast, the sensitivity analyses found that the primary meta-analysis results were not affected by restriction to first episodes of AP, the proportion of patients with pre-existing DM, the proportion of patients who had undergone pancreatic intervention or the use of direct, indirect or FFE tests to diagnose EPI. None of these factors significantly affected statistical heterogeneity.

Meta-regression Analysis {#Sec18}
------------------------

Meta-regression analyses did not identify any significant contributing factor to study heterogeneity by any pre-defined criterion except the year of publication for the follow-up study (Supplementary Table 4).

Publication Bias {#Sec19}
----------------

Funnel plots for publication bias are shown in Supplementary Figure 6. There was no publication bias identified for admission studies (*n* = 10), follow-up studies (*n* = 39) or OAC severe AP patients (Begg-Mazumdar and Egger tests *P *\> 0.1). There was significant publication bias for the follow-up studies of OAC mild AP patients (both Begg-Mazumdar and Egger tests *P* \< 0.05).

Discussion {#Sec20}
==========

By combining data from a total of 41 studies, we found EPI in over half (62%) of all AP patients during their index admission, including patients of all grades of severity. One third (35%) of all AP patients were found to have EPI during follow-up, significantly more after severe AP compared with mild AP or necrotizing AP compared with edematous AP. Note that EPI was not restricted to patients who had extensive pancreatic necrosis, as almost half (46%) of patients who had mild AP were found to have EPI during their index admission and one fifth during follow-up. Patients who had pancreatic necrosis ≥ 50%, underwent necrosectomy and head necrosectomy had increased, but not statistically significantly, RR of EPI compared with those who had necrosis \< 50%, conservative procedures and body/tail necrosectomy, respectively. The prevalence of EPI and new-onset pre-diabetes/diabetes was similar in studies reporting both complications.

There was a progressive decrease in the prevalence of EPI during the follow-up period, to about half at 5 years. Beyond 5 years, prevalence rose modestly, which may have resulted from a focus on more severe and/or progressive disease evidenced by biased reports for mild AP from our publication bias analysis. These data show that recovery from EPI after AP may take many months. AP can be associated with patchy necrosis of many different cell types in the pancreatic parenchyma, exacerbated in inflammation, with disruption of the normal microscopic architecture and complex, coordinated machinery of secretion \[[@CR65]\]. The high prevalence of EPI in patients with AP during their index admission is consistent with such microscopic changes and their effects on exocrine function. There are many data indicating that the murine exocrine pancreas has the capacity to recover or regenerate after experimental AP, but no direct evidence of human exocrine pancreatic regeneration after AP has previously been provided \[[@CR65]\]. There is thus a notable and consistent decrease in the prevalence of EPI over the first 12 months after index admission, which is likely to result from resolution of inflammation, repair, remodeling and regeneration. However, it is also noteworthy that at 5 years this recovery remains incomplete in over a third of affected patients, including 15--20% of all those who had mild AP. In these patients EPI persists and can increase in the long term.

Estimates of the prevalence of EPI after AP made without formal exocrine function tests may be misleading. For example, a large population-based study \[[@CR66]\] from Taiwan included 12,284 patients after a first episode of AP, of whom 94% had OAC mild AP and 46% were prescribed PERT for EPI during follow-up. A US multicenter retrospective study of 167 patients found 30 (28%) of 106 who had a first episode of necrotizing AP were subsequently prescribed PERT for EPI \[[@CR67]\]. In contrast, an Italian multicenter retrospective questionnaire study of 631 patients found 10 (2%) of 558 who had OAC mild AP and 6 (8%) of 73 who had severe AP developed overt steatorrhea \[[@CR68]\]. In a meta-analysis investigating the relationship between exocrine and endocrine failure after AP \[[@CR14]\], summary data from a total of 8 studies including 234 patients identified new-onset pre-diabetes and/or DM in 91 (41% of 221 identified by standard criteria or requirement for therapy) and EPI (by either formal exocrine function testing or reported requirement for PERT) in 59 (27% of 220). This study did not explore the impact of gender, etiology or AP severity, EPI during the index admission, the progression of EPI over time, the role of PERT or the potential effects of EPI on quality of life. The recent meta-analysis by Hollemans et al. \[[@CR6]\] used diagnostic laboratory testing for EPI and found a pooled prevalence of EPI was 27.1% of 1495 AP patients analyzed at 36 months (median).

An alcohol etiology had a twofold RR for EPI after AP compared with other etiologies. This is consistent with the repeated injury that occurs with prolonged and excessive consumption of alcohol \[[@CR69]\] with the risk of atrophy and fibrosis. In these patients there is an increased risk of recurrent AP and/or chronic pancreatitis \[[@CR12]\]. Smoking, more common among those who consume excess alcohol, is known to increase the risk of chronic pancreatitis \[[@CR70]--[@CR72]\]. Given that repair and the reduction in EPI occurs over many months, it is important to cease alcohol consumption and to maintain prolonged abstinence. This is supported by the low incidence of EPI (6%) during long-term follow-up of abstinent patients who had alcohol-associated AP \[[@CR73]\].

Regarding testing (direct and indirect) for EPI, all the tests found similar prevalence rates for EPI except FE-1. This was used in more recent studies and identified a significantly lower prevalence of EPI. While the FE-1 test is easy to perform and cost-effective for RAC severe patients (sensitivity and specificity \> 90%) \[[@CR74]\], the sensitivity for RAC mild/moderately severe AP is low (\~60%) and fails to identify many patients with EPI.

Subgroup and sensitivity analyses did not alter our findings, despite the significant heterogeneity between studies. Tests used to diagnose EPI contributed to this heterogeneity, but it was not possible to determine the contribution of the definitions and methods of identification of etiology, application of severity classification, follow-up periods and time points of investigation. Nor did we contact authors for further data, as we considered it highly unlikely that this would alter our principal findings.

The prevalence and persistence of EPI after AP indicate that up to a third of patients are at risk of malnutrition and malabsorption for prolonged periods after AP, and they may well increase after 5 years. AP induces many catabolic responses, resolution of which EPI may delay; the longer EPI persists, the greater the potential impact of malabsorption and malnutrition; thus, early PERT requirement may be indicated. Hollemans et al. \[[@CR6]\] and our findings confirm that EPI may develop after AP of any severity, justifying routine symptom enquiry and a simple test of exocrine pancreatic function during follow-up, e.g., the FE-1 test.

Apart from the limitations reported by Hollemans et al. \[[@CR6]\] for such a meta-analysis, different methods used to measure EPI may create the high heterogeneity between studies. Also, healthy inequalities that may cause unexplained heterogeneity were rarely reported by the included studies. This study also highlighted the high prevalence of EPI during AP admission regardless of disease severity, and there was a lack of studies to investigate the effect of PERT on EPI during admission and at follow-up.

In conclusion, there is a significant and largely unrecognized prevalence of EPI after AP. Taking into account the data from this study and other published studies, a number of practical recommendations can be made:EPI should be tested for in all patients with AP before discharge from index admission, irrespective of the predicted severity.PERT may be considered for patients with persistent EPI (e.g., FE-1 \< 100--200 µg/g) after AP has resolved. Patients who were likely to develop persistent EPI included those with moderately severe and severe AP, those with pancreatic necrosis, those who have had a necrosectomy and those with an alcohol etiology.Re-testing for EPI (off treatment) should be done at 3 months after discharge in all patients, e.g., a normal FE-1 test result would mean that PERT can be discontinued. For those who remain on PERT, testing should be repeated at 6 and 12 months.

These recommendations will require prospective validation studies, but withholding PERT until further evidence is available is not justified. Further research is needed to refine diagnostic methods for EPI, to determine optimal PERT strategies and to address the impact of health inequalities.
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